Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note published on Wednesday. The brokerage issued a hold rating on the stock.

A number of other brokerages have also weighed in on ONCT. Northland Securities restated a “market perform” rating and issued a $2.00 price objective on shares of Oncternal Therapeutics in a report on Thursday, September 12th. HC Wainwright decreased their price target on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Northland Capmk cut Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Finally, Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.00.

Oncternal Therapeutics Stock Performance

Shares of Oncternal Therapeutics stock opened at $0.75 on Wednesday. The company has a 50-day simple moving average of $1.33 and a two-hundred day simple moving average of $4.71. The stock has a market capitalization of $2.21 million, a PE ratio of -0.06 and a beta of 1.33. Oncternal Therapeutics has a 52-week low of $0.62 and a 52-week high of $13.14.

Hedge Funds Weigh In On Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC acquired a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.